Press Releases

BIO today thanks House champions of the Farm Bill energy title and congratulates them on final passage of the bill.

The Environmental Protection Agency (EPA) lacks authority to waive the overall 2014 volume requirements for the Renewable Fuel Standard, particularly when production and supply of advanced biofuels continues to grow, BIO emphasized in official comments filed today.

The Farm Bill conference report contains significant funding for renewable energy programs, allows renewable chemical technologies to access the programs, and supports purpose grown energy crops.

Updated Convention features include new session formats, premier networking opportunities and improved programming

Thirty-one Senators and 31 Congressmembers signed letters to EPA Administrator Gina McCarthy protesting the proposed rule for the 2014 Renewable Fuel Standards.

BIO announced plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 16th annual BIO CEO & Investor Conference.

BIO and WBBA commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.

Spending plan would enable the FDA to access $85 million in sequestered user fees

BIO expresses strong support for the “Bipartisan Congressional Trade Priorities Act of 2014”, which was issued by a bipartisan group of leaders from the Senate Finance and House Ways and Means Committee last week. 

Nature Biotechnology published a peer-reviewed paper co-authored by the BIO Industry Analysis and BioMedTracker (BMT) highlighting results of a study showing that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2011 is near one in 10.

BIO today echoed the request by the Secretaries of Energy, Agriculture and the Navy for funding and transfer authority for the Department of Energy to participate in the public-private partnership to commercialize biofuels for military use.

More than 140 Companies Expected to Present Their Story to Top Public and Venture Capital Investors

BIO applauds the House of Representatives for passing a bipartisan budget deal, which raises discretionary budget caps, which should provide the Food and Drug Administration  with complete access to its user fees for FYs '14 and '15. 

Hastings highlighted the need to advance the regulatory environment so that it fosters biopharma innovation. Among his recommendations, Hastings emphasized the need to eliminate the sequestration of industry user fees and expedite drug development for serious and life-threatening diseases by expanding the existing Accelerated Approval pathway and by facilitating the new Breakthrough Therapy Designation process.

BIO announced this year’s Fireside Chats lineup for the 16th annual BIO CEO & Investor Conference. The chats will feature a set of candid, one-on-one conversations between biopharma leaders and analysts, followed by an interactive question and answer session. 

BIO's testimony to the EPA public hearing for the 2014 RFS volumes highlighted the jobs, investments and environmental benefits that will be lost if biofuel volumes are rolled back.

BIO and the American Seed Trade Association (ASTA) announced today that the Data Use and Compensation Agreement (DUCA) is open for signature. 

BIO issued the following statement regarding the Innovation Act (H.R. 3309), as reported by the House Judiciary Committee.

BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.

San Diego Interim Mayor Todd Gloria to discuss regional growth and economic impact of biotech industry and the return of the BIO International Convention in 2014.

The EPA's 2014 rule for the Renewable Fuel Standard turns the logic of the program on its head and jeopardizes the progress the industry has made in commercializing advanced biofuels.

Rep. Scott Peters (D-Calif.), who represents an area of San Diego with a large cluster of biotechnology companies, will give opening remarks at BIO's Pacific Rim Summit on Industrial Biotechnology, being held in San Diego in early December.

The Pennsylvania Senate Public Health and Welfare Committee approved Senate Bill 405, which would require a pharmacist to notify the patient and, within 72 hours, the patient’s physician of any biologic product substitution.

The Bill will spur capital formation for small public companies